Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01E: Belzutifan in Solid Tumors
NCT07700758Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Jan 2034
- Countries
- 6
01
Overview
A Phase 2 trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), gastrointestinal stromal tumor (GIST), von Hippel–Lindau disease (VHL), sponsored by Merck & Co.. Started Oct 2026; status: recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)gastrointestinal stromal tumor (GIST)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT07700758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700758.